FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
Executive Summary
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.
You may also be interested in...
Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.
Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.